Related Experiment Video
Updated: Apr 26, 2026
07:25
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
17.0K
Biosimilars: where we were and where we are
Rodeina Challand1, Hazel Gorham, John Constant
1a Biosimilars Development-Scientific Affairs , PRA Health Sciences , Reading , Berkshire , United Kingdom.
Journal of Biopharmaceutical Statistics
|July 19, 2014
Summary
This overview examines biosimilar development, covering regulatory history and scientific challenges. It highlights progress in biosimilar trial design and implementation for complex biological medicines.
Area of Science:
- Biopharmaceutical Science
- Regulatory Science
Background:
- The development of biosimilars has evolved significantly.
- Understanding the history of regulatory pathways is crucial for current biosimilar approvals.
Purpose of the Study:
- To provide an overview of recent advancements in biosimilar development.
- To discuss the historical context and evolution of biosimilar regulations.
- To address scientific considerations and challenges in biosimilar trial design and implementation.
Main Methods:
- Literature review of biosimilar development.
- Analysis of regulatory guidelines and historical issues.
- Examination of scientific and operational challenges in clinical trials.
Main Results:
- Progress has been made in establishing regulatory frameworks for biosimilars.
- Specific scientific and operational issues unique to biosimilar trials have been identified.
- Advancements in trial design and implementation strategies are emerging.
Conclusions:
- The field of biosimilars requires continuous adaptation of regulatory and scientific approaches.
- Addressing the complexities of biosimilar trial design is key to successful market entry.
- Ongoing research and development are essential for the future of biosimilars.
Related Concept Videos
01:28Drug Products: Biologics, Biosimilars and Interchangeables
369
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
369
01:16Bioequivalence: Overview
2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K
01:13Bioequivalence studies: Biowaivers
429
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
429
01:26Pharmaceutical Equivalents
272
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
272
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
230
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
230
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
226
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
226